ANI Pharmaceuticals vs Supernus
ANIP and SUPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and SUPN compare
ANI Pharmaceuticals grew revenue faster over the last twelve months (25.9% versus 16.3% for Supernus).
Supernus keeps more of each dollar of sales as profit, with a net margin of 32.8% compared with 11.2% at ANI Pharmaceuticals.
ANI Pharmaceuticals scores higher on the StockData Score (15 against 6 for Supernus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | SUPN |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | – |
| Share price | $71.44 | $29.72 |
| Change, 1 year | −18.1% | −1.3% |
| Change, 5 years | 64.1% | – |
| Beta (5Y) | 0.61 | 0.70 |
| Employees | 970 | 838 |
| StockData Score | ||
| Total score | 15 (better) | 6 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.5× | – |
| P/S | 1.6× | – |
| P/B | 2.6× | – |
| EV/EBITDA | 6.1× | – |
| P/FCF | 8.0× | – |
| FCF yield | 12.5% | – |
| Fair value | $153.69 | – |
| Margin of safety | 53.5% | – |
| Growth | ||
| Revenue growth (TTM) | 25.9% (better) | 16.3% |
| Revenue growth, 5Y average | 33.5% | – |
| Net income growth (TTM) | 188% | 252% (better) |
| EPS growth (TTM) | 225% | 253% (better) |
| Profitability | ||
| Gross margin | 61.1% | 85.0% (better) |
| Operating margin | 16.0% | 40.6% (better) |
| Net margin | 11.2% | 32.8% (better) |
| FCF margin | 19.7% (better) | 2.3% |
| Return on equity | 20.4% | – |
| Return on invested capital | 23.0% | – |
| Financial health | ||
| Debt / equity | 0.47 | – |
| Net debt / EBITDA | −0.49 | 0.32 (better) |
| Interest coverage | 5.4× | 32.8× (better) |
| Current ratio | 2.75 (better) | 0.61 |
| Altman Z-score | 2.57 | – |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Payout ratio | 0.00% | – |
| Buyback yield | 1.2% | – |
| Shareholder yield | 1.2% | – |
| Ownership | ||
| Held by institutions | 100% | 104% |
| Held by insiders | 12.3% | 16.4% |
| Insider net buying, 12 months | −$13.6M | −$2.5M (better) |
| Short interest, % of float | 17.8% | – |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- SUPN stock overview
- SUPN income statement
- SUPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.